The DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) Trial; [Studie DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure)]
The result's identifiers
Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00159816%3A_____%2F23%3A00079491" target="_blank" >RIV/00159816:_____/23:00079491 - isvavai.cz</a>
Result on the web
<a href="https://www.iakardiologie.cz/artkey/kar-202303-0010_studie_deliver_dapagliflozin_evaluation_to_improve_the_lives_of_patients_with_preserved_ejection_fraction_hear.php" target="_blank" >https://www.iakardiologie.cz/artkey/kar-202303-0010_studie_deliver_dapagliflozin_evaluation_to_improve_the_lives_of_patients_with_preserved_ejection_fraction_hear.php</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.36290/kar.2023.009" target="_blank" >10.36290/kar.2023.009</a>
Alternative languages
Result language
čeština
Original language name
The DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) Trial
Original language description
The results of the DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) trial were presented at the 2022 European Cardiology Congress. The trial tested the effect of dapagliflozin in patients with heart failure and preserved ejection fraction. A total of 6263 patients were randomised to placebo or dapagliflozin. Dapagliflozin significantly decreased worsening of heart failure or cardiovascular death rates. The latest data show that the mechanism of action of gliflozins is much broader than expected, especially the metabolic effect. This has been confirmed by the EMPEROR Preserved and DELIVER trials. Professor Braunwald called SGLT2 inhibitors the statins of the 21st century.
Czech name
The DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) Trial
Czech description
The results of the DELIVER (Dapagliflozin Evaluation to Improve the Lives of Patients with Preserved Ejection Fraction Heart Failure) trial were presented at the 2022 European Cardiology Congress. The trial tested the effect of dapagliflozin in patients with heart failure and preserved ejection fraction. A total of 6263 patients were randomised to placebo or dapagliflozin. Dapagliflozin significantly decreased worsening of heart failure or cardiovascular death rates. The latest data show that the mechanism of action of gliflozins is much broader than expected, especially the metabolic effect. This has been confirmed by the EMPEROR Preserved and DELIVER trials. Professor Braunwald called SGLT2 inhibitors the statins of the 21st century.
Classification
Type
J<sub>SC</sub> - Article in a specialist periodical, which is included in the SCOPUS database
CEP classification
—
OECD FORD branch
30200 - Clinical medicine
Result continuities
Project
—
Continuities
I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace
Others
Publication year
2023
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů
Data specific for result type
Name of the periodical
Intervenční a akutní kardiologie
ISSN
1213-807X
e-ISSN
—
Volume of the periodical
22
Issue of the periodical within the volume
3
Country of publishing house
CZ - CZECH REPUBLIC
Number of pages
4
Pages from-to
151-154
UT code for WoS article
—
EID of the result in the Scopus database
2-s2.0-85179034721